Concerns with use of compounded pergolide
Pergolide has been the drug of choice to treat PPID.1 However, until PRASCEND® (pergolide mesylate) became available, no drug specifically has been approved by the FDA for treating horses with PPID in the US. As a result, compounded pergolide mesylate has been the only product available to veterinarians. But now, there is another option—PRASCEND.
Compounded preparations, unlike FDA-approved products, are not supported by clinically controlled studies used to demonstrate safety and efficacy in the labeled animal species for the specified condition.
Furthermore, since they are not approved by the FDA, compounded products are not required to meet consistency in manufacturing specifications between compounding companies or even between each dose. The lack of therapeutic consistency, stability, and quality control requirements present serious concerns for practitioners.2
Studies show inconsistent strength and stability of compounds
In a study conducted by Drs. Stanley and Knych, liquid, capsule, and powder formulations of pergolide mesylate were tested.3 Samples were obtained from 7 compounding pharmacies. Two samples of each formulation were ordered and stored at various temperatures to test the difference in concentration of the active ingredient, pergolide mesylate, over time.
A new choice offers proven stability
FDA-approved PRASCEND offers a reassuring new treatment option. PRASCEND is rigorously tested to be safe and effective for use in horses and ponies to treat clinical signs associated with PPID.4 It's produced by a leading manufacturer in state-of-the-art facilities with strict adherence to manufacturing guidelines. You can count on each batch of PRASCEND to be of the same high quality and strength you expect. When you prescribe PRASCEND, it's easy to calculate just the right amount to give your patients for the results you and your clients want.